Botulinum Toxin Injections for Refractory Raynaud's Phenomenon in Connective Tissue Disease Patients

Dr. Lachance, an assistant professor at Harvard Medical School and director of the Connective Tissue Disease Clinic, discusses the use of botulinum toxin injections for treating refractory Raynaud's phenomenon, particularly in patients with connective tissue diseases such as systemic sclerosis. The presentation highlights the effectiveness of botulinum toxin in improving pain and digital ulcers, comparing its cost-effectiveness to that of conventional IV vasodilator therapies. Dr. Lachance emphasizes the urgency of treating digital ulcers in these patients due to the risk of severe complications, likening their onset to a medical emergency. While studies show that botulinum toxin can significantly reduce Raynaud's episodes and improve patient quality of life, she acknowledges that it may not be effective for everyone, pointing to variability in patient responses. Detailed technical instructions for administering the injections are provided, recommending the use of topical anesthesia and proper injection techniques into the neurovascular bundles. Dr. Lachance also covers the potential side effects, including temporary soreness and weakness, and discusses challenges related to insurance coverage for the treatment. The talk concludes with a structured treatment algorithm, advocating for a multimodal approach to managing severe Raynaud's symptoms, and reiterates the importance of documentation in securing insurance approvals. Overall, botulinum toxin is presented as a valuable tool in the management of Raynaud's phenomenon, with practitioners encouraged to consider its use in appropriate patient populations.